iRhythm Holdings (IRTC) Receives Positive Ratings from Morgan Stanley and Evercore ISI, With Upside Potential of 35% and 38% Respectively.

iRhythm Holdings (NASDAQ:IRTC) is a digital healthcare company that develops and commercializes device-based Zio biosensor technology for diagnosing cardiac arrhythmias. Morgan Stanley maintained its Overweight rating and assigned a price target of $205, representing a 35% upside from the current level. Evercore ISI revised its rating to Outperform and adjusted its price target estimate from $194 to $210, offering an upside potential above 38%. The company posted revenues of around $207 million in the fourth quarter, outperforming consensus estimates.